Equities

Sedana Medical AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Sedana Medical AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)8.62
  • Today's Change-0.17 / -1.93%
  • Shares traded72.31k
  • 1 Year change-53.90%
  • Beta1.2375
Data delayed at least 15 minutes, as of Mar 02 2026 13:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sedana Medical AB (publ) is a Sweden-based medical technology company. It develops, markets and sales medical devices and conducts drug development for future projects around AnaConDa technology. The AnaConDa technology delivery enables of volatile anaesthetics to invasively ventilated patients. The products portfolio comprises disposable medical devices AnaConDa for administration of volatile anaesthetics, AnaConDa syringes, FlurAbsorb charcoal filters for removing halogenated hydrocarbon anaesthetic gases, different lines and connectors which can be used to connect the FlurAbsorb filter, adaptors, among others. The Company’s main shareholders are board members, Linc AB and Magiola Consulting AB.

  • Revenue in SEK (TTM)200.23m
  • Net income in SEK-59.24m
  • Incorporated2004
  • Employees122.00
  • Location
    Sedana Medical AB (publ)Vendevagen 89DANDERYD 182 32SwedenSWE
  • Phone+46 812405200
  • Fax+46 812405296
  • Websitehttps://sedanamedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Modulight Oyj75.41m-49.11m506.44m71.00--1.06--6.72-0.12-0.120.18741.050.1341-1.014.54---8.73-11.40-9.39-12.14132.06125.90-65.10-126.563.79--0.0588--72.63-6.8228.59--15.83--
Bactiguard Holding AB228.77m-7.84m540.16m153.00--1.9413.772.36-0.2238-0.22386.538.990.3813.446.911,495,216.00-1.31-8.02-1.86-10.1363.7848.56-3.43-25.101.38-0.33870.3410---12.644.2273.69---17.92--
Gentian Diagnostics ASA167.55m12.58m578.28m63.0046.702.9727.233.450.84590.845911.3513.290.72311.566.36--5.43-0.04836.25-0.05555.6447.277.51-0.07883.81--0.0866--16.0722.75-70.73--10.72--
Optomed Oyj182.36m-70.83m612.18m111.00--2.39--3.36-0.3374-0.33740.86881.120.53632.875.07154,009.00-20.83-17.19-25.75-20.6963.6064.81-38.85-34.212.03-8.910.1014--13.675.61-21.83--5.30--
BioPorto A/S52.20m-123.91m639.68m48.00--11.70--12.26-0.1973-0.19730.0830.07740.41322.554.69962,131.60-98.08-65.22-133.92-88.7463.9064.15-237.40-222.221.71--0.1916--17.076.36-21.15---20.56--
Nanexa AB36.15m-11.39m655.87m15.00--6.39570.3218.14-0.0724-0.07240.22550.62370.314416.225.232,409,933.00-9.90-31.63-12.96-38.7886.0296.94-31.50-218.011.51-3.210.0109--48.3972.5054.27--3.54--
Senzime AB (publ)104.02m-137.42m707.47m50.00--2.32--6.80-0.9396-0.93960.70731.940.26192.617.48---34.60-36.25-37.96-39.0233.3524.11-132.11-271.043.04-7.450.044--77.8961.95-15.74--123.16--
OssDsign AB180.16m-50.99m715.75m32.00--2.31--3.97-0.5493-0.54932.062.800.51090.36726.955,629,938.00-14.46-25.42-16.05-28.5996.2985.57-28.30-82.426.33-13.770.0044--34.5148.59-2.68--24.28--
Omda AS450.83m-28.74m773.95m260.00--23.9527.501.72-1.51-1.5123.591.630.679326.5921.701,772,075.00-4.33-5.14-5.39-6.6393.6991.09-6.37-10.320.64830.52810.9359--3.4515.80-163.95---15.57--
Nexstim Oyj107.36m-3.02m823.35m40.00--24.18116.287.67-0.042-0.0421.470.44260.85530.56134.66251,616.80-2.40-12.40-4.17-20.7694.3695.09-2.81-16.291.080.78350.6002--20.5521.1432.79--15.13--
Sedana Medical AB (publ)200.23m-59.24m873.17m122.00--0.9694--4.36-0.5964-0.59642.029.070.20291.387.181,641,205.00-6.00-5.16-6.33-5.4371.2770.03-29.59-32.032.66-1.280.0052--12.017.15-455.03---5.91--
C Rad AB442.00m10.40m875.25m110.0085.712.5942.281.980.31040.310413.2510.280.89284.292.404,018,182.002.107.012.999.8151.9546.992.357.122.771.550.02642.44-5.7814.80-81.40-6.08----
Genovis AB128.95m23.50m1.14bn36.0048.474.2131.958.860.35690.35691.964.110.3656----3,581,861.006.6613.377.2414.8289.8488.5218.2225.11---------1.0816.14-28.6129.52----
Paxman AB (publ)295.08m4.92m1.19bn142.00185.002.7748.174.020.27570.275714.2618.380.84863.454.712,810,305.001.370.84261.601.2067.3468.751.610.79664.071.710.02450.0020.4124.30382.5570.92-3.73--
BICO Group AB1.55bn-1.58bn1.26bn567.00--0.737--0.8132-22.38-15.4321.9824.780.33794.283.392,735,450.00-34.50-8.09-45.17-9.1735.6150.56-102.09-32.511.15-0.74980.424---13.32---1,383.19------
Data as of Mar 02 2026. Currency figures normalised to Sedana Medical AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

29.92%Per cent of shares held by top holders
HolderShares% Held
Lannebo Kapitalf�rvaltning AB (Sweden)as of 31 Dec 20257.48m7.53%
Premier Fund Managers Ltd.as of 20 Oct 20254.97m5.00%
Swedbank Robur Fonder ABas of 30 Oct 20244.67m4.70%
Lancelot Asset Management ABas of 31 Dec 20242.85m2.87%
AMF Fonder ABas of 31 Dec 20242.49m2.51%
Highclere International Investors LLPas of 31 Mar 20252.27m2.29%
Handelsbanken Fonder ABas of 31 Jan 20261.98m2.00%
Skandia Investment Management ABas of 28 Nov 20251.61m1.62%
Fortezza Finanz AGas of 30 Jun 2025800.00k0.81%
SEB Funds ABas of 30 Jan 2026603.30k0.61%
More ▼
Data from 31 Dec 2024 - 02 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.